120 related articles for article (PubMed ID: 21293504)
1. Pancreatic cancer in 2010: new insights for early intervention and detection.
Costello E; Neoptolemos JP
Nat Rev Gastroenterol Hepatol; 2011 Feb; 8(2):71-3. PubMed ID: 21293504
[TBL] [Abstract][Full Text] [Related]
2. Response of pancreatic carcinoma to 5-fluorouracil and leucovorin.
Grinblatt DL; Benson AB
Am J Med; 1992 Jan; 92(1):107-9. PubMed ID: 1731500
[No Abstract] [Full Text] [Related]
3. Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2).
André T; Noirclerc M; Hammel P; Meckenstock R; Landi B; Cattan S; Selle F; Codoul JF; Guerrier-Parmentier B; Mokhtar R; Louvet C;
Gastroenterol Clin Biol; 2004; 28(8-9):645-50. PubMed ID: 15646530
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215
[No Abstract] [Full Text] [Related]
5. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
Usón Junior PLS; Rother ET; Maluf FC; Bugano DDG
Clin Colorectal Cancer; 2018 Sep; 17(3):187-197. PubMed ID: 29615310
[TBL] [Abstract][Full Text] [Related]
7. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
8. A comparison of two dose regimens in pancreatic cancer.
Figer A; Sadikov E; Mishaeli M; Koren R; Gal R; Levin I; Klein B
J Chemother; 2000 Oct; 12(5):442-5. PubMed ID: 11128566
[TBL] [Abstract][Full Text] [Related]
9. Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Yu K
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):9-10. PubMed ID: 30807562
[No Abstract] [Full Text] [Related]
10. Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Lima CMSR
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):3-5. PubMed ID: 30807559
[No Abstract] [Full Text] [Related]
11. Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer.
Reni M; Macchini M; Porcu L
JAMA Oncol; 2023 Mar; 9(3):435-436. PubMed ID: 36701148
[No Abstract] [Full Text] [Related]
12. A patient with a metastatic gastroenteropancreatic endocrine carcinoma causing hyperinsulinaemic hypoglycaemia and the carcinoid syndrome.
Hinchliffe E; Allcock RL; Mansoor W; Myers MA
Ann Clin Biochem; 2011 Nov; 48(Pt 6):579-83. PubMed ID: 21948491
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma.
Maiello E; Gebbia V; Giuliani F; Testa A; Giotta F; Gebbia N; Colucci G
Clin Ter; 1998; 149(5):351-5. PubMed ID: 10052247
[TBL] [Abstract][Full Text] [Related]
14. Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply.
Conroy T; Castan F; Hammel P
JAMA Oncol; 2023 Mar; 9(3):436-437. PubMed ID: 36701135
[No Abstract] [Full Text] [Related]
15. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous regression of pancreatic cancer with liver metastases.
Saade Lemus P; Anderson K; Smith M; Bullock A
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31154349
[TBL] [Abstract][Full Text] [Related]
17. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
[TBL] [Abstract][Full Text] [Related]
18. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
[TBL] [Abstract][Full Text] [Related]
19. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
